Home/Pipeline/LT3001

LT3001

Acute Ischemic Stroke

Phase 2Active

Key Facts

Indication

Acute Ischemic Stroke

Phase

Phase 2

Status

Active

Company

Lumosa Therapeutics

About Lumosa Therapeutics

Taiwan biotech advancing breakthrough stroke and pain therapies with a strong licensing and co‑development model.

View full company profile

Therapeutic Areas

Neuroscience Oncology Cardiovascular

Other Acute Ischemic Stroke Drugs

Drug	Company	Phase	Status
Presendin™ (Exenatide)	Invex Therapeutics	Phase 2	Active
Supernova Stent Retriever	Gravity Medical Technology	Commercial	Active
Neutron Reperfusion Catheter	Gravity Medical Technology	Commercial	Active
AST-004	Astrocyte Pharmaceuticals	Phase 1/2	IND cleared March 2024
scp776	Silver Creek Pharmaceuticals	Phase 2	Active
VB-001	VST Bio	Pre-clinical	Active
Pulse NanoMED for AIS	Euphrates Vascular	Pre-clinical	Active
NeVa NET	Vesalio	Development/Commercial	Active
ApTOLL	aptaTargets	Phase 2	Transferred
ThermoSuit® for Acute Ischemic Stroke	Life Recovery Systems HD	Pivotal Trial (Planned)	Active
Pulsante for Ischemic Stroke	Realeve	Research/Clinical Study	Active
Glenzocimab (ACT017)	Acticor Biotech	Phase 2/3	Active